Dmitry Balyasny’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Dmitry Balyasny’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12,970	Closed	-$106K	–	1853
2018 Q3	$106K	Buy	+12,970	New	+$99.6K	﹤0.01%	1605
2018 Q1	–	Sell	-168,500	Closed	-$2.11M	–	2415
2017 Q4	$2.11M	Buy	168,500 +59,916	+55%	+$687K	0.01%	1124
2017 Q3	$908K	Buy	+108,584	New	+$1.15M	﹤0.01%	1191

Other funds holding ZYNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIM

Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Dmitry Balyasny's ZYNE Position: Q4 2018 in Review

Dmitry Balyasny sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2018, closing a stake of 12,970 shares — an estimated $106K sold.

Dmitry Balyasny first reported a position in ZYNE in Q3 2017 and held it in 3 quarters. The position peaked at $2.11M in Q4 2017. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2018.

Dmitry Balyasny reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
Dmitry Balyasny sold 12,970 Zynerba Pharmaceuticals, Inc shares in Q4 2018, an estimated $106K.
Dmitry Balyasny first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and held it in 3 quarters.
Dmitry Balyasny's Zynerba Pharmaceuticals, Inc position peaked at $2.11M in Q4 2017.
62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2018.

Based on Balyasny Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.